- IN₹264.60bn
- IN₹237.64bn
- IN₹22.81bn
- 92
- 11
- 98
- 78
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 36.36 | ||
| PEG Ratio (f) | 3.64 | ||
| EPS Growth (f) | 11.1% | ||
| Dividend Yield (f) | 0.95% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.27 | ||
| Price to Tang. Book | 7.22 | ||
| Price to Free Cashflow | 41.89 | ||
| Price to Sales | 11.6 | ||
| EV to EBITDA | 31.47 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.99% | ||
| Return on Equity | 19.65% | ||
| Operating Margin | 30.43% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 22,385.5 | 26,109.9 | 24,247.6 | 21,931.7 | 22,813.5 | 23,966 | 26,433.15 | 1.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +1.82 | +23.16 | -1.7 | -8.5 | +16.47 | +10.23 | +13.31 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Directors
- Milind Patil FID
- Prajeet Nair CCO
- S. Sridhar MDR
- Aijaz Tobaccowalla EDR (46)
- Samir Kazi DRC
- Sunil Lalbhai IND
- Pradip Shah IND (68)
- Uday Khanna NID (71)
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- November 21st, 1950
- Public Since
- December 9th, 1994
- No. of Shareholders
- 112,075
- No. of Employees
- 1,598
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 45,747,732
- Address
- Pfizer Centre, 5, Patel Estate, MUMBAI, 400051
- Web
- https://www.pfizerltd.co.in/about-pfizer/our-manufacturing
- Phone
- +91 2266932000
- Contact
- Prajeet Nair
- Auditors
- BSR & Co. LLP
Upcoming Events for PFIZER
Dividend For PFIZ.NS - 35.0000 INR
Pfizer Ltd Annual Shareholders Meeting
Q1 2026 Pfizer Ltd Earnings Release
Q2 2026 Pfizer Ltd Earnings Release
Similar to PFIZER
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Pfizer share price?
As of Today at 13:38 UTC, shares in Pfizer are trading at IN₹5,784.00. This share price information is delayed by 15 minutes.
How has the Pfizer share price performed this year?
Shares in Pfizer last closed at IN₹5,784.00 and the price had moved by +25.19% over the past 365 days. In terms of relative price strength the Pfizer share price has outperformed the S&P BSE 100 Index by +20.73% over the past year.
What are the analyst and broker recommendations for Pfizer?
The overall consensus recommendation for Pfizer is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pfizer dividend yield?
The Pfizer dividend yield is 0.61% based on the trailing twelve month period.
Does Pfizer pay a dividend?
Last year, Pfizer paid a total dividend of IN₹35.00, and it currently has a trailing dividend yield of 0.61%.Looking ahead, shares in Pfizer are due to go ex-dividend on 2025-07-09 and the next dividend pay date is 2025-07-25.
When does Pfizer next pay dividends?
Pfizer are due to go ex-dividend on 2025-07-09 and the next dividend pay date is 2025-07-25. The historic dividend yield on Pfizer shares is currently 0.61%.
How do I buy Pfizer shares?
To buy shares in Pfizer you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pfizer?
As of the previous close price of IN₹5,784.00, shares in Pfizer had a market capitalisation of IN₹264.60bn.
Where are Pfizer shares listed?
Here are the trading details for Pfizer:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: PFIZER
What kind of share is Pfizer?
Based on an overall assessment of its quality, value and momentum Pfizer is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pfizer share price forecast for 2025?
The analyst consensus target price for shares in Pfizer is IN₹6,241.67. That is 7.91% above the last closing price of IN₹5,784.00.
Analysts covering Pfizer currently have a consensus Earnings Per Share (EPS) forecast of IN₹153.70 for the next financial year.
Find out moreWhat is the trend in the Pfizer share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pfizer. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +3.63%.
As of the last closing price of IN₹5,784.00, shares in Pfizer were trading +17.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pfizer PE Ratio?
The Pfizer PE ratio based on its reported earnings over the past 12 months is 36.36. The shares last closed at IN₹5,784.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pfizer?
Pfizer's management team is headed by:
- Milind Patil - FID
- Prajeet Nair - CCO
- S. Sridhar - MDR
- Aijaz Tobaccowalla - EDR
- Samir Kazi - DRC
- Sunil Lalbhai - IND
- Pradip Shah - IND
- Uday Khanna - NID